только для медицинских специалистов

Консультант врача

Электронная медицинская библиотека

Раздел 12 / 12
Страница 6 / 6

Библиография

  1. Pollack C.V. Jr., Reilly P.A., van Ryn J., et al. Idarucizumab for dabigatran reversal – Full cohort analysis. N. Engl. J. Med. 2017; 377: 431–41.
  2. Vosko M.R., BocksruckerС., Drwiła R., et al. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran treated. J. Thromb. Thrombolysis. 2017;
  3. Deborah M. Siegal, M.D., John T. Curnutte, M.D., Ph.D., Stuart J. Connolly, M.D., et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity N Engl J Med 2015; 373:2413-2424 DOI: 10.1056/NEJMoa151099143: 306–317.
  4. SigrunHalvorsen, Robert F. Storey, Bianca Rocca, et a. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis, European Heart Journal, Volume 38, Issue 19, 14 May 2017, Pages 1455–1462, https://doi.org/10.1093/eurheartj/ehw454
  5. Airaksinen KE, Gronberg T, Nuotio I, Nikkinen M, Ylitalo A, Biancari F, Hartikainen JE. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. J Am CollCardiol 2013;62: 1187–1192
  6. Berger M1, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol. 1998 Dec 15;82(12):1545-7, A8.
  7. Nuotio I, Hartikainen JE, Grönberg T et al Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA. 2014 Aug 13;312(6):647-9. doi: 10.1001/jama.2014.3824.
  8. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015 Oct;17(10):1467-507. doi: 10.1093/europace/euv309. Epub 2015 Aug 31
  9. A Goette, H Heidbuchel. Practical Implementation of Anticoagulation Strategy for Patients Undergoing Cardioversion of Atrial Fibrillation. Arrhythmia & Electrophysiology Review 2017;6(2):50–4. DOI: 10.15420/aer.2017:3:2
  10. Renda G, Zimarino M, Ricci F1, et al Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. Am J Med. 2016 Oct;129(10):1117-1123.e2. doi: 10.1016/j.amjmed.2016.05.007. Epub 2016 Jun 2.
  11. Weigner MJ, Thomas LR, Patel U et al Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: short-term safety and impact on maintenance of sinus rhythm at 1 year. Am J Med. 2001 Jun 15;110(9):694-702.
  12. Wu LA, Chandrasekaran K, Friedman PA, et al Safety of expedited anticoagulation in patients undergoing transesophageal echocardiographic-guided cardioversion. Am J Med. 2006 Feb;119(2):142-6.
  13. Jaber WA, Prior DL, Thamilarasan M, et al Efficacy of anticoagulation in resolving left atrial and left atrial appendage thrombi: A transesophageal echocardiographic study. Am Heart J. 2000 Jul;140(1):150-6.
  14. Barysienė J, Žebrauskaitė A, Petrikonytė D, et al. Findings of transoesophageal echocardiogram in appropriately anticoagulated patients with persistent atrial fibrillation prior to planned cardioversion. BMC CardiovascDisord. 2017 Feb 23;17(1):67. doi: 10.1186/s12872-017-0503-8
  15. Weigner MJ, Caulfield TA, Danias PG, et al Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med. 1997 Apr 15;126(8):615-20

  1. Ezekowitz MD, Pollack CV Jr, Halperin JL5 et al Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial Eur Heart J. 2018 Aug 21;39(32):2959-2971. doi: 10.1093/eurheartj/ehy148.
  2. Fauchier L, Cinaud A, Brigadeau F, et al. Left Atrial Appendage Closure in Atrial Fibrillation. J Am CollCardiol. 2018 Dec 4;72(22):2806-2807. doi: 10.1016/j.jacc.2018.08.2196.
  3. Cappato R, Marchlinski FE, Hohnloser SH, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015;36:1805–1811
  4. Calkins H, Willems S, Gerstenfeld EP, et al. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med 2017;376:1627–1636.
  5. Kirchhof P, Haeusler KG, Blank B, et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. European Heart Journal, Volume 39, Issue 32, Pages 2942–2955, https://doi.org/10.1093/eurheartj/ehy176
  6. Hohnloser SH, Camm J, Cappato R, et al. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. Eur Heart J. 2019 Apr 11. pii: ehz190. doi: 10.1093/eurheartj/ehz190. [Epub ahead of print]
  7. Torn M, Rosendaal FR. Oral anticoagulation in surgical procedures: risks and recommendations. Br J Haematol 2003;123:676–682
  8. Di BiaseL, Burkhardt JD,Santangeli P, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation 2014;129:2638–2644
  9. Franz-Josef Neumann, Miguel Sousa-Uva, Anders Ahlsson, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization, European Heart Journal, Volume 40, Issue 2, 07 January 2019, Pages 87–165, https://doi.org/10.1093/eurheartj/ehy394